Patients aged 65 years or older at baseline had a lower risk of nonfatal MI and nonfatal stroke with canagliflozin versus placebo (P for heterogeneity, .02 and.01, respectively), according to investigators. Older patients also had lower risk of the composite of serum creatinine doubling, end-stage kidney disease, or renal death with canagliflozin versus placebo (P = .01).
Patients aged less than 65 years at baseline had lower risk of cardiovascular death (P = .01) and all cause mortality (P = .01) for canagliflozin versus placebo.
Dr. Ovalle reported disclosures related to Merck, AstraZeneca, Sanofi Pasteur, Novo Nordisk, GlaxoSmithKline, Janssen, Eli Lilly, Medtronic, Pfizer, and GI Dynamics, along with the National Institutes of Health and Juvenile Diabetes Research Foundation.
SOURCE: Ovalle F et al. AACE 2018, Abstract 233.